Cargando…
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Solid cancers are the most common types of cancers diagnosed globally and comprise a large number of deaths each year. The main challenge currently in drug development for tumors raised from solid organs is to find more selective compounds, which exploit specific molecular targets. In this work, the...
Autores principales: | Sochacka-Ćwikła, Aleksandra, Mączyński, Marcin, Regiec, Andrzej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000317/ https://www.ncbi.nlm.nih.gov/pubmed/35408658 http://dx.doi.org/10.3390/molecules27072259 |
Ejemplares similares
-
FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021) -
New Oxazolo[5,4-d]pyrimidines as Potential Anticancer Agents: Their Design, Synthesis, and In Vitro Biological Activity Research
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2022) -
Synthesis, Physicochemical Characteristics and Plausible Mechanism of Action of an Immunosuppressive Isoxazolo[5,4-e]-1,2,4-Triazepine Derivative (RM33)
por: Mączyński, Marcin, et al.
Publicado: (2021) -
Synthesis and Biological Activity of New 7-Amino-oxazolo[5,4-d]Pyrimidine Derivatives
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2020) -
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
por: Wu, Qing, et al.
Publicado: (2022)